Can a multiple sclerosis drug help preserve insulin production in type 1 diabetes?
NCT ID NCT07258394
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether dimethyl fumarate, a drug already used for multiple sclerosis, can protect the pancreas's insulin-producing cells in adults recently diagnosed with type 1 diabetes. Ninety participants will take either the drug or a placebo twice daily for 24 weeks, alongside their usual insulin. The main goal is to see if the drug helps maintain natural insulin production, measured by a C-peptide test after a mixed meal.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dimethyl fumarate
What this could lead to
If it works, this could help preserve the body's ability to produce some insulin, potentially reducing the amount of insulin injections needed.
What could go wrong
This is an early Phase 3 trial with only 90 participants. The drug may not protect beta cells better than placebo, and side effects like flushing or stomach issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Deparement of Endocrinology and Metabolism, The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••